Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Mesenchymal stromal cell exosomes prevent and revert experimental pulmonary fibrosis through modulation of monocyte phenotypes
Nahal Mansouri, Gareth R. Willis, Angeles Fernandez-Gonzalez, Monica Reis, Sina Nassiri, S. Alex Mitsialis, Stella Kourembanas
Nahal Mansouri, Gareth R. Willis, Angeles Fernandez-Gonzalez, Monica Reis, Sina Nassiri, S. Alex Mitsialis, Stella Kourembanas
View: Text | PDF
Research Article Pulmonology Stem cells

Mesenchymal stromal cell exosomes prevent and revert experimental pulmonary fibrosis through modulation of monocyte phenotypes

  • Text
  • PDF
Abstract

Mesenchymal stromal/stem cell (MSC) therapy has shown promise in experimental models of idiopathic pulmonary fibrosis (IPF). The aim of this study was to test the therapeutic effects of extracellular vesicles produced by human BM MSCs (MEx) in a bleomycin-induced pulmonary fibrosis model and investigate mechanisms of action. Adult C57BL/6 mice were challenged with endotracheal instillation of bleomycin and treated with MEx concurrently, or for reversal models, at day 7 or 21. Experimental groups were assessed at day 7, 14, or 28. Bleomycin-challenged mice presented with severe septal thickening and prominent fibrosis, and this was effectively prevented or reversed by MEx treatment. MEx modulated lung macrophage phenotypes, shifting the proportions of lung proinflammatory/classical and nonclassical monocytes and alveolar macrophages toward the monocyte/macrophage profiles of control mice. A parallel immunomodulatory effect was demonstrated in the BM. Notably, transplantation of MEx-preconditioned BM-derived monocytes alleviated core features of pulmonary fibrosis and lung inflammation. Proteomic analysis revealed that MEx therapy promotes an immunoregulatory, antiinflammatory monocyte phenotype. We conclude that MEx prevent and revert core features of bleomycin-induced pulmonary fibrosis and that the beneficial actions of MEx may be mediated via systemic modulation of monocyte phenotypes.

Authors

Nahal Mansouri, Gareth R. Willis, Angeles Fernandez-Gonzalez, Monica Reis, Sina Nassiri, S. Alex Mitsialis, Stella Kourembanas

×

Figure 7

MEx therapy reprograms monocytes to a nonclassical (Ly6Cneg) phenotype.

Options: View larger image (or click on image) Download as PowerPoint
MEx therapy reprograms monocytes to a nonclassical (Ly6Cneg) phenotype.
...
(A) BM-derived myeloid cells (BMDMy) were isolated from 6- to 8-week-old FVB mice, cultured ex vivo for 3 days to drive the monocytic lineage, and treated with MEx (MEx dose: 1 × 106 MSC equivalents) or media alone on day 1 (D1) and day 2 (D2). (B) Flow cytometric analysis of BM-derived monocytes (BMDMo) after 3 days of culture showed that > 90% were CD45+CD11b+ cells. Student’s t test (2 tailed) . To assess the direct effect of MEx on monocyte phenotype, BMDMo were treated with 2 doses of MEx or FEx on days 1 and 2, and cells were processed for liquid chromatography–tandem mass spectrometry (LC-MS/MS) on day 3, as shown in A. (C) Eighty-four peptides where deemed differentially abundant in MEx-treated BMDMo vs. FEx-treated controls at FDR < 0.25. (D) Gene set analysis revealed that genes encoding for peptides abundant in MEx-treated BMDMo were, on average, overexpressed in the Ly6Cneg monocytes (P < 0.001), whereas genes encoding for peptides abundant in the FEx-treated BMDMo were, on average, overexpressed in the Ly6Cpos monocytes (P < 0.001) . Transcriptome data were obtained from GSE95411.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts